Article Text
Statistics from Altmetric.com
QUESTION: In patients with left ventricular dysfunction, does adding carvedilol to the management of myocardial infarction (MI) reduce mortality and non-fatal MI?
Design
Randomised {allocation concealed*}†, blinded (patients, judicial assessors of outcomes, data analysts),* placebo controlled trial with a mean 1.3 years of follow up.
Setting
163 centres in 17 countries.
Patients
1959 patients (mean age 63 y, 74% men) participated. Inclusion criteria were age > 18 years; stable and definite MI occurring 3 to 21 days before randomisation; left ventricular ejection fraction ≤ 0.40; wall-motion-score index ≤ 1.3; current treatment with angiotensin-converting enzyme (ACE) inhibitors for ≥ 48 hours with a stable dose for ≥ 24 hours; and if the patient was having heart failure treatment with diuretics and …